Blog

Intangible Assets, Earn-Outs in BioPharma Acquisitions

Sorbus Advisors LLC studied purchase price allocations in biopharmaceutical industry titled “Valuation of Goodwill and Intangibles in 2015 BioPharmaceutical Transactions.” The study focused on recognition, valuation, and determination of useful lives of pertinent intangible assets, contingent considerations and goodwill.

While no two acquisitions are the same, common themes in the valuation of intangibles and goodwill can be found along industry lines. Biopharmaceutical companies with the focus on drug development rely on such identifiable intangible assets as developed technology, in-process research and development (in-process R&D), and marketed products. Fair value analysis may be required for less common non-compete agreements and trade names.

Contingent considerations, or earn-outs, often account for a substantial portion of the purchase consideration. It is recorded as a liability. Fair value estimation is performed as of the transaction date and marked to market at the end of each consecutive reporting period. Similarly, in-process R&D has to be valued (or tested for impairment) each reporting period until reclassified into developed product or abandoned.

Relative valuations of goodwill and identifiable intangibles are also consistent within the biopharmaceutical industry. It is common to find a significant portion of excess consideration to be ascribed to goodwill. Marketed products, developed technology and in-process R&D will dependent on the state of therapeutic product pipeline, platform technology and extent of commercial operations.

Download the paper to see the results: HERE.

More Updates

Six Purchase Price Allocation Issues to Know

AI may not catch up with valuations for purchase accounting very soon. We can credit changing best practices and a steady flow of non-authoritative guidance. They always bring fresh considerations and new calculations to explore. Yet, there are real practical implications for clients to consider.

Secondary Transactions and Valuations

Stock pickers believe they can value assets better than the market. The research shows otherwise. The financial accounting rules don’t play around and require observable transaction values to be the primary indicators. This topic is relevant for most privately held security valuations, including broad fair value issues, IRC 409A valuations, portfolio valuations, and tax.

Navigating SAFE Valuations

Neither “Safe” nor “Simple,” these Simple Agreements for Future Equity are convertible debt instruments that are often misunderstood and hard to value.

Schedule a Call

Most new projects will require a brief introductory conversation. Unless you are a returning client asking for an update to a old valuation, please use the calendar below to schedule a call with us:

Send a Message

We are located in the San Francisco Bay Area, while our clients cover much broader geography, from Southern California to the East Coast and Europe. Please contact us with questions and inquiries. Also, feel free to stop by on your way to the beautiful Sonoma or Napa Valley.

Schedule a Call